Clinical trials: Breast Cancer in Situ
Breast Cancer
Gefitinib Followed By Surgery in Treating Women With Ductal Carcinoma In Situ of the Breast
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ.
- Trial name
- NCT00082667
- Testing
- gefitinib, Surgery
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
Partial-Breast Radiation Therapy in Treating Women With Early-Stage Breast Cancer
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. It may also cause less damage to normal tissue.
- Trial name
- NCT01008514
- Testing
- adjuvant therapy, accelerated partial breast irradiation, intracavitary balloon brachytherapy
- Sponsor
- Ohio State University Comprehensive Cancer Center
Melanoma, Squamous Cell Carcinoma of the Head and Neck
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
The purpose of this study is to test the safety of a course of injections containing Poly-ICLC in patients with advanced solid tumors that can be easily and safely reached with a needle.
- Conditions
- Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin
- Trial name
- Hiltonol (NCT01984892)
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nina Bhardwaj
Female Breast Carcinoma, Female Ductal Carcinoma In Situ
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
This is an open-label, non-randomized pharmacokinetic study of fulvestrant in women scheduled for mastectomy or lumpectomy. Eligible subjects will be identified with breast cancer or DCIS.
- Trial name
- 007 (NCT02540330)
- Testing
- Fulvestrant
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Atossa Therapeutics, Inc.
Early Stage Breast Cancer (Stage 0-III)
Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory
The proposed study compares the outcomes of a physical activity intervention begun at diagnosis, continuing through active cancer treatment and into six months of survivorship compared to the outcomes of a control group receiving…
- Trial name
- NCT01157130
- Testing
- Exercise Regimen
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Nevada Cancer Institute
Outcome of Breast Cancer
Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer
A prospective observational longitudinal study of 464 patients was performed between 2010 and 2015. Patients with invasive ductal carcinoma (IDC) and ductal carcinoma in situ associated to invasive ductal carcinoma (DCIS +IDC)…
- Trial name
- NCT03669952
- Testing
- None intervention
- Volunteers
- 464 people
- Sponsor
- Omphis Foundation
Breast Neoplasms
Intra-operative Radiotherapy For Breast Cancer Women After NSM
The role of NSM is still controversial, mainly because of concern about the oncologic safety of the nipple-areola complex (NAC).INTRABEAM (Carl Zeiss, Oberkochen, Germany) is the most widely used mobile intraoperative…
- Trial name
- NCT02389686
- Testing
- INTRABEAM (Carl Zeiss, Oberkochen, Germany)
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Liao Ning
Breast Cancer Stage 0, Breast Cancer Stage I
Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making
This trial studies how well a breast cancer surgery decision aid works in increasing patient engagement in decision making for patients with newly diagnosed stage 0-III breast cancer.
- Conditions
- Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT03766009
- Testing
- Usual Care, Web-based decision aid
- Where
- 58 sites in United States, Guam and 1 more
- Volunteers
- 627 people
- Sponsor
- Alliance for Clinical Trials in Oncology
DCIS
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
- Trial name
- ELISA (NCT04797299)
- Where
- 24 sites in Canada
- Volunteers
- 526 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer
Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Giving radiofrequency ablation before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be…
- Trial name
- NCT00388115
- Testing
- conventional surgery, neoadjuvant therapy, radiofrequency ablation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
DCIS, Invasive Breast Cancer
Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity
Microorganisms in the human body (such as virus, bacteria, fungus) may have an important role in breast cancer side effects. In this study, microorganisms will be analyzed to determine which, if any,are present.
- Trial name
- NCT04245150
- Testing
- Stool sample, Skin Swab Sample
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy after surgery is effective in preventing a recurrence of ductal carcinoma in situ.
- Trial name
- NCT00077168
- Testing
- anastrozole, tamoxifen citrate, adjuvant therapy
- Where
- 29 sites in United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Ductal Carcinoma in Situ
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
This will be a proof of principle clinical trial to evaluate the use of pasireotide (SOM230) in women with ductal carcinoma in situ (DCIS) of the breast.
- Trial name
- NCT01372618
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Breast Cancer, Hot Flashes
Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial
RATIONALE: Gathering information about the frequency and intensity of hot flashes in patients with breast cancer and in patients who have a high risk of developing breast cancer may help doctors learn more about menopausal…
- Trial name
- NCT00666913
- Testing
- informational intervention
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Pain
Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: New surgery techniques may lessen pain after breast surgery. It is not yet known whether tumescent mastectomy or standard mastectomy results in less pain in women with breast cancer.
- Conditions
- Breast Cancer, Pain, Perioperative/Postoperative Complications
- Trial name
- NCT00859157
- Testing
- therapeutic conventional surgery
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, Davis
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT06401889
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Breast Cancer
Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer
RATIONALE: Studying samples of nipple fluid, urine, and blood in the laboratory from patients with cancer and from patients at risk of developing cancer may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00897208
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer, DCIS
THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence
The purpose of this study is to pilot and refine an online behavioral intervention based on Positive Affect Training (PAT) that aims to increase positive emotional attitudes and decrease negative emotional attitudes toward…
- Trial name
- THRIVE (NCT06388304)
- Testing
- THRIVE Online PAT Program
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Joanna Arch
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
This phase I trial evaluates the safety and effectiveness of in situ immunomodulation with CDX-301, radiotherapy, CDX-1140 and Poly-ICLC (Cohort A) and these with intravenous (IV) pembrolizumab and subcutaneous (SC) tocilizumab…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma
- Trial name
- NCT04616248
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Southern California
Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer.
- Conditions
- Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7
- Trial name
- NCT01245712
- Testing
- Accelerated Partial Breast Irradiation, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center